# Cadrenal Therapeutics, Inc.: overview CVKD · Nasdaq · CIK 1937993 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/cvkd.md) · [Financials](/companies/cvkd/financials.md) · [Filings](/companies/cvkd/filings.md) · [Insiders](/companies/cvkd/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(2.18)](/filings/0001213900-25-107816.md) | not reported | [(2.09)](/filings/0001213900-26-053074.md) | [(1.87)](/filings/0001213900-26-089153.md) | [(1.31)](/filings/0001213900-25-107816.md) | not reported | [(1.04)](/filings/0001213900-26-053074.md) | [(1.14)](/filings/0001213900-26-089153.md) | | Free cash flow | $k | not reported | not reported | [(4,652)](/filings/0001213900-26-053074.md) | [(3,026) d](/filings/0001213900-26-089153.md) | [(2,359) d](/filings/0001213900-25-107816.md) | [(2,570) d](/filings/0001213900-26-036946.md) | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | | Diluted EPS | $ per share | [(9.29)](/filings/0001213900-25-023759.md) | [(8.73)](/filings/0001213900-26-036946.md) | [(6.64)](/filings/0001213900-26-036946.md) | | Free cash flow | $m | [(3.5)](/filings/0001213900-25-023759.md) | [(7.4)](/filings/0001213900-26-036946.md) | [(12.6)](/filings/0001213900-26-036946.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cvkd/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $167.5k | 50,137 | | Added +4,936 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $63.5k | 19,024 | | Reduced −2,602 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $27.8k | 8,311 | | Unchanged | | [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $4.3k | 1,282 | | Added +889 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $3.7k | 1,112 | | Added +1,109 | | [Grove Bank & Trust](/funds/1662212.md) | 2026-06-30 | $3.3k | 1,000 | | New +1,000 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $2.4k | 706 | | Added +606 | | [Clearstead Advisors, LLC](/funds/842775.md) | 2026-06-30 | $2.2k | 650 | | New +650 | | [Quest 10 Wealth Builders, Inc.](/funds/2035215.md) | 2026-06-30 | $1.3k | 380 | | New +380 | | [OSAIC HOLDINGS, INC.](/funds/1677044.md) | 2026-06-30 | $1.0k | 300 | | Unchanged | ## Recent filings [All 276 filings](/companies/cvkd/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-07 | 13:23 ET | [8-K](/filings/0001213900-26-107442.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-107442 | | 2026-09-29 | 20:05 ET | [8-K](/filings/0001213900-26-104647.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001213900-26-104647 | | 2026-08-31 | 12:29 ET | [8-K](/filings/0001213900-26-095394.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-095394 | | 2026-08-13 | 20:31 ET | [10-Q](/filings/0001213900-26-089153.md) | Quarterly report, period 2026-06-30 | 0001213900-26-089153 | | 2026-08-13 | 20:30 ET | [8-K](/filings/0001213900-26-089147.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-26-089147 | | 2026-08-03 | 21:09 ET | [DEF 14A](/filings/0001213900-26-084710.md) | Proxy statement, period 2026-09-24 | 0001213900-26-084710 | | 2026-07-21 | 12:30 ET | [8-K](/filings/0001213900-26-079824.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-079824 | | 2026-07-17 | 20:15 ET | [8-K](/filings/0001213900-26-079176.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001213900-26-079176 | | 2026-07-10 | 20:05 ET | [8-K](/filings/0001213900-26-077134.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001213900-26-077134 | | 2026-07-01 | 21:23 ET | [8-K](/filings/0001213900-26-074421.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-074421 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-036946.md), filed Mar 31, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1937993 - Tickers: CVKD - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.